Enhertu approved in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies February 5, 2025
NMPA approves Sarclisa + SOC VRd in China for patients with newly diagnosed multiple myeloma ineligible for transplant February 4, 2025
Sarclisa + VRd combo approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant February 3, 2025
Tagitanlimab Approved by NMPA in Combination with Cisplatin and Gemcitabine For the 1L Treatment of Patients with recurrent or metastatic NPC January 28, 2025
Sarclisa + VRd combo approved in the EU to treat transplant-ineligible newly diagnosed multiple myeloma January 23, 2025
FDA Approves Lumakras® (Sotorasib) + Vectibix® (Panitumumab) For Chemorefractory KRAS G12C-Mutated Metastatic CRC January 21, 2025
Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma January 21, 2025
European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer January 21, 2025
Datroway (datopotamab deruxtecan) approved in the US for patients with previously treated metastatic HR+ve, HER2-neg breast cancer January 21, 2025
Sarclisa obtains NMPA approval in China for the treatment of adult patients with R/R multiple myeloma January 14, 2025
DATROWAY Approved in Japan for Patients with Previously Treated Unresectable or Recurrent HR+ve, HER2neg Breast Cancer January 7, 2025
European Commission approves RYBREVANT (amivantamab) + LAZCLUZE (lazertinib) for the 1L treatment of patients with EGFR-mutated advanced NSCLC January 7, 2025
China’s NMPA Approves VYLOYTM (zolbetuximab) for 1L Treatment of Advanced Gastric or GEJ Adenocarcinoma January 7, 2025
TEVIMBRA Approved in US for 1L Treatment of Gastric and GEJ Cancers in Combination with Chemotherapy December 31, 2024
EC approves Opdivo + Yervoy for the 1L Treatment of Adult Patients with MSI-H or dMMR Metastatic CRC December 31, 2024
US FDA Approves SC Opdivo Qvantig (nivolumab & hyaluronidase-nvhy) Injection in Most Previously Approved Adult, Solid Tumor Opdivo Indications December 31, 2024
FDA approves Itovebi for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation December 26, 2024
U.S. FDA Approves BRAFTOVI Combination Regimen as 1L Treatment of BRAF V600E-Mutant mCRC December 25, 2024
Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer December 25, 2024
FDA Approves UNLOXCYT™ (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma December 18, 2024
Neoadjuvant KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemo, Then Continued as Monotherapy as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC December 17, 2024
